Sinopharm Group CoSHTDF -2.67%78 Current Ratio is 1.41 as of Dec. 2025, which is 6% above its 10-year median of 1.33. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 120 Medical Distribution companies, Sinopharm Group Co ranks better than 52.5% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sinopharm Group Co's current ratio for the quarter that ended in Dec. 2025 was 1.41.
Sinopharm Group Co has a current ratio of 1.41. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sinopharm Group Co's Current Ratio or its related term are showing as below:
SHTDF'
s Current Ratio Range Over the Past 10 Years
Min: 1.28 Med: 1.33 Max: 1.41
Current: 1.41
During the past 13 years, Sinopharm Group Co's highest Current Ratio was 1.41. The lowest was 1.28. And the median was 1.33.
SHTDF's Current Ratio is ranked better than 52.5% of 120
companies
in the Medical Distribution industry
Industry Median: 1.4
vs SHTDF: 1.41
Sinopharm Group Co (OTCPK:SHTDF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sinopharm Group Co Current Ratio Related Terms
Sinopharm Group Co Current Ratio Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Current Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a Current Ratio of 1.41 as of Dec. 2025. This is near median its historical median of 1.33. Over the past decade, Sinopharm Group Co's Current Ratio has ranged from 1.28 to 1.41. According to the industry distribution chart, Sinopharm Group Co ranks #57 out of 120 companies in the Medical Distribution industry, placing it in the top 47.5%.
Is Sinopharm Group Co's Current Ratio too high?
Sinopharm Group Co's current Current Ratio of 1.41 is near median its 10-year median of 1.33. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 1.41. The Medical Distribution industry median Current Ratio is 1.40. Sinopharm Group Co's value of 1.41 is 0.7% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #57 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Current Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #57 out of 120 companies for Current Ratio. This puts Sinopharm Group Co in the upper half of its industry. The industry median Current Ratio is 1.40. Sinopharm Group Co's value of 1.41 is 0.7% above this benchmark. Historically, Sinopharm Group Co's own Current Ratio has ranged from 1.28 to 1.41 over the past decade. While the company's 10-year median is 1.33 vs. the industry median of 1.40, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Distribution company?
The median Current Ratio among Medical Distribution companies is 1.40, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Current Ratio of 1.41 is 0.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Current Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Current Ratio is 1.41, which is near median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current Current Ratio is 1.41, which is near median its 10-year median of 1.33 and 0.7% above the Medical Distribution industry median of 1.40. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Current Ratio is 1.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Current Ratio: 1.41 (near median its 10-year median of 1.33)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 0.7% above the Medical Distribution median (#57 of 120)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
